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Celiac disease (CD) is frequently diagnosed in patients with type 1 diabetes (T1D), and T1D patients can exhibit Abs against tissue
transglutaminase, the auto-antigen in CD. Thus, gliadin, the trigger in CD, has been suggested to have a role in T1D pathogenesis.
The objective of this study was to investigate whether gliadin contributes to enteropathy and insulitis in NOD-DQ8 mice, an animal
model that does not spontaneously develop T1D. Gliadin-sensitized NOD-DQ8 mice developed moderate enteropathy, intraepithe-
lial lymphocytosis, and barrier dysfunction, but not insulitis. Administration of anti-CD25 mAbs before gliadin-sensitization in-
duced partial depletion of CD25+Foxp3+ T cells and led to severe insulitis, but did not exacerbate mucosal dysfunction. CD4+
T cells isolated from pancreatic lymph nodes of mice that developed insulitis showed increased proliferation and proinflammatory
cytokines after incubation with gliadin but not with BSA. CD4+ T cells isolated from nonsensitized controls did not response to
gliadin or BSA. In conclusion, gliadin sensitization induced moderate enteropathy in NOD-DQ8 mice. However, insulitis de-
velopment required gliadin-sensitization and partial systemic depletion of CD25+Foxp3+ T cells. This humanized murine model
provides a mechanistic link to explain how the mucosal intolerance to a dietary protein can lead to insulitis in the presence of
partial regulatory T cell deficiency. The Journal of Immunology, 2011, 187: 4338–4346.
T
he environmental factors that trigger most autoimmune
diseases remain unknown. One exception is celiac disease
(CD), which is one of the most common autoimmune
disorders (1). CD is caused by the ingestion of gluten, a mixture of
wheat proteins composed of gliadin and glutenin (1–4). Genetic
factors also have a crucial role in CD pathogenesis (4). Almost all
patients with CD carry HLA-DQ2 or HLA-DQ8, and these alleles
contribute 40% of disease susceptibility (5). HLA-DQ8 and -DQ2
heterodimers confer susceptibility to CD by presenting a set of
toxic gliadins and glutenins to specific CD4+ T lymphocytes.
Adult CD diagnoses have dramatically increased in North
America because of increased diagnostic efficiency and increased
prevalence. CD is now a public health concern with a prevalence
of ∼1% among North Americans (2, 6).
Type 1 diabetes (T1D) is an autoimmune disease that results
from a T cell-mediated attack of b cells in pancreatic islets. As
with CD, there is a strong genetic component to T1D, of which
the HLA class II genes DQ and DR play a major role (7). These
susceptibility genes are thought to be important regulators of im-
mune responses (8). However, the declining proportion of newly
diagnosed disease in children with high-risk genotypes suggests
that environmental factors have an important pathogenic role in
T1D, but the exact triggers remain largely unclear (9).
CD and T1D are comorbid conditions (10–12). CD is diagnosed
in 3–11% of T1D patients, and ∼10% of children and 2% of adults
with T1D exhibit Abs against tissue transglutaminase (tTG), the
autoantigen in CD (3, 10, 13–15). The association between CD and
T1D has been attributed to their similar genetic basis (16–18).
HLA haplotypes, such as DR3-DQ2, have been associated with
defective oral tolerance and enhanced immune responses to di-
etary proteins (19, 20). Intriguingly, parallel birth cohort studies
showed that infants at genetic risk for CD and T1D are at greater
risk of either disease when exposed early to dietary cereals (21,
22). A genotyping study that enrolled 8064 T1D patients and 9339
control subjects showed that patients with T1D and CD express
seven common alleles that regulate autoimmune responses (23,
24). Thus, genetic predisposition may confer susceptibility through
DQ2/DQ8 HLA and non-HLA mechanisms that involve dysregu-
lated immune responses to gut-encountered Ags (25). Studies
in clinical and T1D animal models have proposed that exposure
to gliadin in the diet contributes to diabetes in genetically suscep-
tible hosts (22, 23, 26–29).
In this study, we used mice that lack all mouse endogenous class
II molecules, but express the human DQ8 gene, in the autoimmune
predisposing background of NOD mice (30) to investigate the role
of gliadin-sensitization in the development of enteropathy and
insulitis. In contrast to NOD mice, a validated animal model of
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diabetes (31, 32), NOD-DQ8 mice do not spontaneously develop
diabetes (33, 34). Our findings demonstrate that gliadin-sensitization
resulted in barrier dysfunction and moderate enteropathy, but no
insulitis. However, a partial depletion of regulatory T cells before
gliadin sensitization induced severe insulitis. The presence of
gliadin-responsive T cells in the pancreatic lymph nodes (PLNs)
of mice that develop insulitis suggests that gliadin-specific T cell
reactivity has a role in insulitis development in this model.
Materials and Methods
Mice
Transgenic male mice that express HLA-DQ8 in an endogenous MHC class
II-deficient background were backcrossed to NOD mice for 10 generations
and intercrossed to produce congenic NOD AB˚ DQ8 mice (33). Eight- to
10-wk-old male mice were used for experiments. Mice were weaned and
maintained on a low-fat (4.4%), gluten-free diet, purchased from Harlan
Laboratories and bred in a conventional, specific pathogen-free colony at
McMaster University. Fourteen-week-old male NOD mice, 6-wk-old NOD
mice, and 14-wk-old nonobese resistant (NOR) mice (obtained from Dr.
J. Danska, Hospital for Sick Children, Toronto, ON, Canada) were used in
additional experiments as positive and negative controls, respectively, for
the development and evaluation of insulitis. Glycemic status was moni-
tored weekly using a glucometer (Abbott Diabetes Care) and was de-
termined at the time of sacrifice using a Roche modular instrument. All
experiments were conducted with approval from the McMaster University
Animal Care Committee.
Anti-CD25 Ab treatment
Prior to gliadin sensitization, mice received two i.p. injections of mono-
clonal anti-CD25 Abs (PC61, 250 mg; Leinco Technologies, St. Louis,
MO), 1 wk apart. This procedure induces a partial depletion of CD4+
CD25+Foxp3+ T cells and induces an immune dysregulation. Control
groups were pretreated with two i.p. injections of PBS (250 ml) 1 wk apart.
Gliadin sensitization
Oneweek after anti-CD25Ab treatment, micewere sensitized with a peptic-
tryptic digest of gliadin (PT-gliadin). PT-gliadin was prepared as described
previously (35). Gliadin (Sigma-Aldrich) was dissolved in endotoxin-free
0.2 N HCl for 2 h in a 37˚C water bath with 1 g pepsin (Sigma-Aldrich).
After 2 h of digestion, the pH was adjusted to 7.4 using endotoxin-free 2 M
NaOH. Trypsin (Sigma-Aldrich) was added, the solution was boiled vig-
orously for 30 min, and the PT-gliadin was stored at 220˚C. To sensitize
the mice, they were gavaged with 500 mg PT-gliadin plus 25 mg cholera
toxin (Sigma-Aldrich) once per week for 3 wk. Gliadin-sensitized mice
were switched to a gluten-containing diet at the time of sensitization.
Another set of mice was sensitized with 500 mg BSA (Sigma-Aldrich) plus
25 mg cholera toxin once per week for 3 wk. Control groups were gavaged
with 25 mg cholera toxin only. Control groups were maintained on a glu-
ten-free diet throughout the experiments.
Glucose tolerance test
To determine impaired glucose tolerance, mice were fasted for 6 h. Mice
were then injected with glucose (Sigma-Aldrich) i.p. at a dose of 1 g/kg.
Venous plasma glucose was checked prior to glucose injection, and at
20, 40, 60, 90, and 120 min after glucose injection (36). Blood glucose
levels were tested using a glucometer (Abbott Diabetes Care). Glucose
tolerance tests were conducted after the third gliadin-sensitization.
FACS analysis
One week after the second anti-CD25 Ab injections, cell suspensions of
spleen, mesenteric lymph nodes (MLNs) and PLNs were prepared in RPMI
1640 (1% Penstrep, 10% FCS, 2 mM L-glutamine) by passing organs
through a 100-mm nylon mesh screen to dissociate the cells. Suspensions
were depleted of RBCs by lysis and resuspended in FACS buffer (PBS
containing 0.1% azide and 2% BSA). Cells were stained with
fluorochrome-labeled cell-surface Abs including CD4-allophycocyanin
(RM4-5), CD8a-PerCP (53-6.7), and CD25-PE (7D4) for 30 min at 4˚C
(BD Biosciences-Pharmingen). For intracellular staining, cells were per-
meabilized using the Foxp3 staining buffer set (eBioscience) and incubated
with FITC-conjugated Abs toward Foxp3 (FJK-16s; eBioscience) for 90
min at 4˚C. Stained cells were acquired using the LSR II (BD Biosciences)
and analyzed with FlowJo software (TreeStar).
Histologic evaluation
Cross-sections of the proximal small intestine were fixed in 10% formalin,
embedded in paraffin, and stained with H&E for histologic evaluation by
light microscopy. Two sections of the proximal small intestine were
evaluated for evidence of inflammation, and villus-to-crypt ratios were
determined. Twenty villus-to-crypt ratios were measured for each mouse in
a blinded fashion. CD3+ intraepithelial lymphocytes (IELs) per 20 enter-
ocytes in five randomly chosen villus tips were counted according to the
previously described methods and expressed as IEL/100 enterocytes (37).
The pancreas was removed, fixed in 10% formalin, and embedded in
paraffin. Sections of the pancreas were stained with H&E for histologic
evaluation and assessment of insulitis. As described previously, insulitis
was determined by evaluating islet infiltration from grade 0–4: 0, no in-
filtration; 1, perivascular or periductal infiltrates; 2, leukocyte penetration
of up to 25% islet mass; 3, leukocytes penetration of up to 75% of islet
mass; 4, end-stage insulitis with ,20% of islet mass remaining (38–40).
An average insulitis score was determined for each group of mice. The
liver and lungs were also removed and fixed in formalin. Sections were
embedded in paraffin and stained with H&E and evaluated for signs of
inflammation. Slides were viewed by light microscopy (Olympus), and
images were acquired and analyzed using Image Pro Plus.
Immunohistochemistry for CD3+ cells
Immunostaining for CD3+ cells was performed on paraffin sections to
detect the presence of IELs in sections of the proximal small intestine as
described previously (41). Paraffin sections were incubated overnight at
4˚C with rabbit anti-mouse primary Abs to CD3 (1:2000; Dako); this was
followed by incubation with HRP conjugated anti-rabbit Abs. The Abs
were visualized using 3-amino-9-ethylcarbazole and counterstained with
Mayer hematoxylin. Negative controls were performed in the absence of
primary Ab. Immunostaining for CD3+ cells was performed on paraffin
sections of the pancreas as described above. Slides were viewed by light
microscopy (Olympus) under 403 magnification. Images were acquired
and analyzed using Image Pro Plus.
Anti-tTg ELISA
tTg was derived from guinea pig liver (Sigma-Aldrich). Transglutaminase
was diluted in PBS and 0.1 mg was added to each well of a 96-well Nunc-
Immuno plate (Nunc). Plates were incubated overnight at 4˚C. Plates were
washed five times with PBS and blocked with 1% BSA in PBS for 1 h at
room temperature. Serum was added to the plates at 50 ml per well and
incubated for 1 h at room temperature. Plates were washed five times, and
secondary anti-mouse IgA (Sigma-Aldrich) Abs were added and incubated
an additional 2 h. Secondary Abs were HRP conjugated, and tetrame-
thylbenzidine was the substrate (SurModics). Positive reactivity was de-
termined using a positive cutoff value of $3 SD above the mean of the
control group (42).
Anti-gliadin ELISA
Gliadin (Sigma-Aldrich) was dissolved in 70% ethanol and then diluted in
PBS. Ninety-six–well Nunc-Immuno plates (Nunc) were coated with gli-
adin by adding 5 mg to each well. The plate was incubated overnight at
4˚C. Plates were washed with PBS-0.05% Tween-20 (PBS-T) and blocked
using 1%BSA in PBS for 1 h at room temperature. Serum was diluted into
1% BSA in PBS either 1:10 for detection of IgA or 1:50 for detection of
IgG and added to plates for 2 h at room temperature. Plates were washed
with PBS-T, and HRP conjugated secondary anti-mouse IgA (Sigma-
Aldrich) or anti-mouse IgG (Sigma-Aldrich) Abs were added to the
wells for 1 h at room temperature. Plates were washed with PBS-T, and
tetramethylbenzidine (SurModics) was used as the substrate.
Ussing chambers
Two sections of jejunum from each mouse were used for Ussing chamber
experiments as described previously (41, 43). A 3–4-cm piece of jejunum
was collected, cut into two sections, and placed in Krebs buffer aerated
with 95% O2 and 5% CO2 (pH 7.3–7.4). Each segment of intestine was cut
open along the mesenteric border to form a flat mucosal sheet and mounted
into an Ussing chamber. The chamber exposed 0.6 cm2 of tissue surface
area to 8 ml of circulating oxygenated Krebs buffer containing 10 mM
glucose (serosal side) and 10 mM mannitol (mucosal side) maintained at
37˚C. Net active transport across the epithelium was measured via a short
circuit current response (Isc, mA) injected through the tissue under
voltage-clamp conditions. Tissue conductance (the passive permeability to
ions) was calculated using Ohm’s law. Baseline Isc (mA/cm2) and con-
ductance (mS/cm2) were recorded at equilibrium, 20 min after mounting
jejunum sections.
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In vitro proliferation assay and cytokine analysis
Cell suspensions of PLNs were prepared in RPMI 1640 (1% penicillin/
streptomycin, 10% FCS, 2 mM L-glutamine) by passing organs through
a 100-mm nylon mesh screen to dissociate cells. CD4+ T cells were iso-
lated from PLNs through negative selection (EasySep Mouse CD4+ T Cell
Enrichment Kit; Stemcell). Cell yield was assessed by FACS analysis, with
an enriched population of 89–96% CD4+ T cells. Isolated CD4+ T cells
were labeled with CFSE as previously described and washed three times
with RPMI 1640 (44). Splenocytes were treated with mitomycin C (Sigma-
Aldrich), and dendritic cells were isolated through positive selection
(Easysep Mouse CD11c Selection Kit, Stemcell). Dendritic cells (5 3 104
cells/well) were cocultured with isolated CD4+ T cells (2 3 105 cells/well)
in the presence of PT-gliadin (500 mg/ml), BSA (500 mg/ml), media alone
in a round-bottom 96-well plate. For positive controls, cells were cultured
with Con A. Cells were cultured for 4 d at 37˚C, 5% CO2. Cells were
harvested on day 4 to assess proliferation by FACS analysis. Cells were
resuspended in FACS buffer and stained with anti–CD4-allophycocyanin
(BD Biosciences-Pharmingen) and 7-AAD (Sigma-Aldrich). CFSE-
labeled cells were acquired using the LSR II (BD Biosciences). Viable
cells, as determined by 7AAD exclusion, were gated on CD4+ T cells.
CFSE intensity for this population was determined using FlowJo software
(TreeStar).
Supernatants from cell cultures were collected at 48 and 96 h. The
presence of proinflammatory cytokines in the supernatant was determined
using a cytometric bead array inflammation kit (BD Biosciences) and
analyzed using BD FACSarray Bioanalyzer System (BD Biosciences). The
presence of TGF-b was determined by ELISA (R&D Systems).
Statistical analysis
Statistical analysis was performed with GraphPad Prism software. For more
than two treatment groups, an ANOVAwith a Bonferroni post hoc test for
multiple comparisons was used. When two groups were compared, an
unpaired t test was used; p , 0.05 was considered significant. Data are
displayed as mean 6 SEM.
Results
Gliadin-sensitized NOD-DQ8 mice developed barrier
dysfunction and altered villus/crypt ratios
We have shown previously that HLA-DQ8 mice develop activation
of the innate and adaptive arms of the immune system, and in-
creased tissue conductance after gliadin sensitization (41, 43, 45).
Despite this finding, gliadin-sensitized HLA-DQ8 mice develop
only a mild enteropathy, characterized by increased IELs, similar
to a Marsh I lesion in CD (46). To determine whether NOD-DQ8
mice develop gliadin-induced barrier dysfunction and enteropathy,
mice were sensitized with a peptic-tryptic digested form of gliadin
once per week for 3 wk. Cholera toxin was used as a mucosal
adjuvant. A group of mice was pretreated with anti-CD25 mAbs
to determine whether a preexisting immune dysregulation could
exacerbate gliadin-induced mucosal dysfunction and enteropathy.
Regulatory T cells (Tregs) are marked by the expression of CD4,
CD25, and the transcription factor Foxp3. Therefore, we define
a Treg as a CD4+CD25+Foxp3+ T cell, and will refer to CD4+
CD25+Foxp3+ T cells as Tregs or CD4+CD25+Foxp3+ Tregs
hereafter. Furthermore, CD25 (IL-2R a subunit) is essential for
the generation, peripheral expansion, and maintenance of Tregs
(47–52). Monoclonal anti-CD25 Abs have been used to deplete
the Treg population (47, 49, 53). Therefore, NOD-DQ8 mice were
treated with two i.p. doses of anti-CD25 mAbs, 1 wk apart, prior
to gliadin sensitization. We used Ussing chambers to measure
tissue conductance in sections of the small intestine. Enteropathy
was evaluated by villus-to-crypt ratios and by immunostaining for
CD3+ IELs (37, 41).
Gliadin-sensitized NOD-DQ8 mice had increased tissue con-
ductance compared with untreated controls and to anti-CD25
treated mice (Fig. 1). No difference in conductance was seen
between untreated controls and anti-CD25 mAb-treated plus BSA-
sensitized mice. There was also no difference in tissue conduc-
tance between gliadin-sensitized mice and sensitized mice that
were pretreated with anti-CD25 mAbs, suggesting that barrier
dysfunction was gliadin-dependent and was not induced by anti-
CD25 mAb treatment. Gliadin-sensitized mice developed lower
villus-to-crypt ratios (Fig. 2) and increased IEL counts (Fig. 3),
reminiscent of a Marsh II lesion, compared with untreated control
mice, anti-CD25 mAb treated mice, and anti-CD25 mAb-treated
plus BSA-sensitized mice. Previous Treg depletion did not further
increase the severity of gliadin-induced enteropathy in NOD-DQ8
mice. These results suggest that, compared with HLA-DQ8 mice,
DQ8 mice on the NOD background are more sensitive to gliadin-
FIGURE 1. Impaired intestinal barrier function in gliadin-sensitized
NOD-DQ8 mice. Sections of small intestine were mounted in Ussing
chambers and tissue conductance (mS/cm2) was measured 24 h after the
final gavage. Each dot represents an individual mouse; p values were
computed using an ANOVAwith a post hoc test for multiple comparisons.
FIGURE 2. Histopathology of the small intestine showing decreased
villus-to-crypt ratio in gliadin-sensitized NOD-DQ8 mice. H&E-stained
sections of the proximal small intestine in untreated controls (A) and anti-
CD25 mAb-treated (B), gliadin-sensitized (C), anti-CD25 mAb treated
plus BSA-sensitized (D), and anti-CD25 mAb treated plus gliadin-sensi-
tized mice (E). Original magnification 310. F, Quantification of villus/
crypt ratios (n = 8 for each group). Data represented as mean 6 SEM;
p values were computed using an ANOVA with a post hoc test for mul-
tiple comparisons. *p , 0.05 versus control mice, anti-CD25 mAb treated
mice, and anti-CD25 + BSA-treated mice.
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induced enteropathy, and partial depletion of Tregs has no evident
role in the induction of enteropathy in the model.
Gliadin-sensitized NOD-DQ8 mice develop anti-gliadin and
anti-tTG Abs
In contrast to anti-gliadin IgA and IgG Abs, IgA autoantibodies
toward tTG are highly specific for CD (54). HLA-DQ8 mice de-
velop anti-gliadin IgG Abs after gliadin-sensitization (41, 45). We
tested whether gliadin sensitization in NOD-DQ8 mice led to the
production of Abs toward gliadin and tTG. Four of 11 gliadin-
sensitized mice developed anti-gliadin IgG Abs in the serum and
three of nine anti-CD25 plus gliadin-sensitized mice developed
anti-gliadin IgG Abs. Anti-gliadin IgG Abs were not detected in
the serum of nonsensitized mice (Fig. 4A). Anti-tTG IgA Abs
were found in the serum of three gliadin-sensitized mice and two
anti-CD25 mAb-treated plus gliadin-sensitized mice. No control,
anti-CD25 mAb treated only, or BSA-sensitized mouse tested
positive for anti-tTG Abs (Fig. 4B). The presence of anti-tTG Abs
in a proportion of gliadin-sensitized mice is in accordance with the
more moderate enteropathy observed in these mice compared with
HLA-DQ8 mice (41).
Anti-CD25 Ab treatment partially depleted CD4+CD25+
Foxp3+ T cells
To confirm that anti-CD25 mAb treatment depleted the regulatory
population, NOD-DQ8 mice were treated with two i.p. doses of
anti-CD25 mAbs, each 1 wk apart. Cells were collected 1 wk
following the second Ab treatment, and the percentage of Tregs
was determined. Similar to previous findings, we showed a partial
depletion of CD4+CD25+Foxp3+ Tregs (Supplemental Fig. 1) (47,
49). Compared with PBS-treated controls, the CD25+Foxp3+ cells
decreased from 10.57 to 2.32% of the total CD4+ lymphocyte
population in the spleen of anti-CD25 mAb-treated mice (Sup-
plemental Fig. 1A, left panels). The remaining Foxp3+ cells
expressed low levels of CD25 or no CD25. In addition, anti-CD25
mAb treatment resulted in the partial depletion of Tregs in the
MLN and PLN. In the MLN, the CD25+Foxp3+ cells decreased
from 11.54 to 3.27% of the CD4+ T cell population (Supplemental
Fig. 1A, center panels). In the PLN, the CD25+Foxp3+ cells de-
creased from 11.94 to 3.0% of the CD4+ T cell population
(Supplemental Fig. 1A, right panels). Thus, anti-CD25 mAb
treatment before gliadin sensitization led to a partial, but signifi-
cant depletion of Tregs in the spleen, MLN, and PLN (Supple-
mental Fig. 1B).
Partial Treg depletion and gliadin sensitization was associated
with insulitis in NOD-DQ8 mice
NOR and NOD mice were used as negative and positive controls,
respectively, to validate the insulitis grading in NOD-DQ8 mice. At
6 wk of age, NOD mice had developed mild periinsulitis (Sup-
plemental Fig. 2A, 2D), while severe insulitis developed at 14 wk
of age (Supplemental Fig. 2B, 2D). NOR mice developed mild
periinsulitis at 14 wk of age (Supplemental Fig. 2C, 2D), as
previously reported (55). Intestinal tissue conductance was sig-
nificantly higher in 14-wk-old NOD mice, but not in 6-wk-old
NOD mice, compared with NOR controls. NOR mice displayed
normal barrier function (Supplemental Fig. 3). Thus, although
NOD mice displayed higher tissue conductance values at the
preinsulitis stage, only at 14 wk of age (insulitis stage) did this
difference become statistically significant.
We investigated whether gliadin-induced mucosal changes were
linked to insulitis in NOD-DQ8 mice. Previous studies have shown
that NOD-DQ8 mice on a gluten-containing diet develop a gliadin-
dependent blistering of the skin, but do not develop diabetes
(33). In addition, gliadin-sensitized HLA-DQ8 mice have shown
FIGURE 3. Immunohistochemistry showing increased number of CD3+
IELs in gliadin-sensitized mice. CD3+-stained sections of the proximal
small intestine in untreated controls (A), anti-CD25 mAb-treated (B),
gliadin-sensitized (C), anti-CD25 mAb-treated plus BSA-sensitized (D),
and anti-CD25 mAb-treated plus gliadin-sensitized mice (E). Original
magnification 340. Black arrows indicate IELs. F, Quantification of CD3+
cells in villi tips, expressed as IEL per 100 enterocytes (n = 8 for each
group). Data are represented as mean 6 SEM; p values were computed
using an ANOVA with a post hoc test for multiple comparisons. **p ,
0.01 versus control mice, anti-CD25 mAb treated mice, and anti-CD25 +
BSA-treated mice.
FIGURE 4. Anti-gliadin and anti-tTG ELISAs. Serum was collected
from NOD-DQ8 mice, and the presence of anti-gliadin IgG Abs (A) and
anti-tTG IgA Abs (B) was determined by ELISA. Anti-gliadin and anti-
tTG positive reactivity was determined using a positive cutoff value of $3
SD above the mean of control mice (dotted line) (40). Each dot represents
an individual mouse.
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increased IL-10 production and increased recruitment of regula-
tory Foxp3+ cells within the lamina propria. It has been hypoth-
esized that this regulatory immune response to gliadin may protect
mice from overt autoimmunity (41, 45). Thus, we used anti-CD25
mAbs to partially deplete the Tregs, which we defined as CD4+
CD25+Foxp3+ T cells (47, 56) prior to gliadin sensitization. Pan-
creatic islets were analyzed for infiltration of immune cells 24 h
after the final gavage. Untreated control mice had normal islets
(Fig. 5A). Anti-CD25 treated mice also had normal islets with no
significant infiltration (Fig. 5B). Similar to the findings of Marietta
et al. (33), gliadin-sensitized mice did not develop severe insulitis
(Fig. 5C). However, mice that were pretreated with anti-CD25
mAbs and subsequently sensitized with gliadin developed severe
insulitis (Fig. 5E). The insulitis scores of anti-CD25 plus gliadin-
sensitized mice were similar to those of 14-wk-old NOD mice
(Supplemental Fig. 2). Treatment of anti-CD25 mAbs plus BSA
sensitization did not lead to insulitis, suggesting that the response
was not induced by an unrelated Ag and was gliadin-dependent
(Fig. 5D). The insulitis scores of anti-CD25 mAb treated plus
gliadin-sensitized mice were greater than those in untreated con-
trols, anti-CD25 mAb treated mice, gliadin-sensitized, and to anti-
CD25 mAb treated plus BSA-sensitized mice (Fig. 5F). The
infiltrates were composed of CD3+ lymphocytes (Fig. 6). No
differences were seen in blood glucose levels (data not shown) or
glucose tolerance between groups (data not shown). These results
suggest that NOD-DQ8 mice are susceptible to developing an
inflammatory response in b-cell islets when systemic partial de-
pletion of CD4+CD25+Foxp3+ cells is induced prior to gliadin
sensitization.
Partial CD4+CD25+Foxp3+ cell depletion and gliadin
sensitization did not lead to widespread autoimmunity
To determine whether inflammation was present in other organs,
H&E-stained sections of the liver and lungs were examined for
signs of infiltration and inflammation. There was no significant
infiltration observed in the liver of nonsensitized controls, anti-
CD25 mAb treated mice, gliadin-sensitized mice, anti-CD25 mAb
treated plus BSA-sensitized mice, or in anti-CD25 mAb plus
gliadin-sensitized mice (data not shown). Similarly, none of the
groups exhibited inflammation within the lungs (data not shown).
Thus, the infiltration observed in anti-CD25 mAb-treated plus
gliadin-sensitized mice was restricted to the pancreas, indicating
an absence of generalized autoimmunity.
T cells from PLNs of NOD-DQ8 mice that developed insulitis
exhibit increased proliferation and proinflammatory cytokine
production when incubated with gliadin
HLA-DQ8 mice have shown increased proliferative responses
toward gliadin peptides in both the spleen and MLN (45, 57).
Evidence suggests that the gut and the pancreas are immunolog-
ically linked. In NOD mice, islet-infiltrating lymphocytes express
the a4b7 integrin, a gut-homing receptor (58). The ligand for
a4b7, MAdCAM-1, is expressed within the pancreas and is
FIGURE 5. Gliadin-sensitized NOD-DQ8 mice develop severe insulitis
in the presence of an immune dysregulation. Insulitis was determined by
evaluating H&E-stained sections of the pancreas for islet infiltration,
scoring each islet from grade 0 (no infiltration) to grade 4 (end-stage
insulitis with ,20% of islet mass remaining) (38–40). An average insulitis
score was determined for each group of mice: untreated controls (A), anti-
CD25 mAb treated mice (B), gliadin-sensitized mice (C), anti-CD25 mAb-
treated plus BSA-sensitized mice (D), and anti-CD25 mAb treated plus
gliadin-sensitized mice (E). Original magnification 310. F, Quantification
of insulitis scores for multiple mice (n = 9 per group). Data are represented
as mean 6 SEM; p values were computed using an ANOVA with a post
hoc test for multiple comparisons.
FIGURE 6. Immunohistochemistry showing the presence of CD3+
lymphocytes in pancreatic islets in NOD-DQ8 mice. Representative CD3+-
stained sections of the pancreas in untreated controls (A), anti-CD25 mAb-
treated (B), gliadin-sensitized mice (C), anti-CD25 mAb plus BSA-sensi-
tized (D), and anti-CD25 mAb-treated plus gliadin-sensitized mice (E).
Original magnification 320.
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upregulated during insulitis (59). These findings suggest
that lymphocytes displaying gut homing markers are able to
circulate between the gut and the pancreas, and that immune
responses to dietary Ags may modulate insulitis. We therefore
determined whether cells in the PLNs of gliadin-sensitized NOD-
DQ8 mice responded to gliadin by measuring proliferation and
cytokine production. CD4+ T cells were isolated from the PLNs of
control mice and anti-CD25 mAb plus gliadin-sensitized mice and
incubated with gliadin, BSA, or media alone. In anti-CD25 mAb
plus gliadin-sensitized mice, gliadin stimulation led to increased
proliferation compared with BSA and media alone. In control
mice, no increase in proliferation was observed in gliadin-
stimulated cultures (Fig. 7A, 7B). Compared with untreated con-
trols, gliadin stimulation increased proliferation in anti-CD25 plus
gliadin-sensitized mice. Cytokine production was measured in the
PLN cell culture supernatants. There was a significant increase in
production of the proinflammatory cytokine TNF-a in the cell
cultures from mice that developed insulitis and were incubated
with gliadin compared with BSA (Fig. 7C). In cultures from mice
that developed insulitis and were cultured with media or BSA, the
production of MCP-1 and IL-6 was below the limit of detection,
whereas incubation with gliadin resulted in detectable levels of
both MCP-1 and IL-6 in some of the mice (Fig. 7D, 7E). No
differences were found in IL-10 or TGF-b production (data not
shown). In PLN cell cultures from control mice, all cytokine levels
were below the limit of detection (data not shown). These results
suggest that gliadin-specific T-cells are found within the PLNs of
mice that develop insulitis and that these cells produce a Th1
cytokine response.
Discussion
The main objective of this study was to investigate the role of
gliadin in the development of enteropathy and insulitis in NOD-
DQ8 mice. T cells in NOD-DQ8 mice are selected in the thy-
mus in a DQ8-restricted manner. The presence of the DQ8 gene
ensures efficient gliadin Ag presentation by APCs to CD4+ T cells
(45, 57, 60). We found that gliadin sensitization in NOD-DQ8
mice induced moderate enteropathy, characterized by decreased
villus-to-crypt ratios and increased IEL counts in the proximal
small intestine. Similar to other DQ8 transgenic mouse models,
NOD-DQ8 mice developed gliadin-induced intestinal barrier
dysfunction. These changes were induced by gliadin, as the im-
mune and functional changes were not observed after sensitization
with an unrelated Ag—BSA. Development of severe insulitis,
however, required partial depletion of CD25+Foxp3+ T cells prior
to gliadin sensitization. T cells isolated from the PLNs of mice
that developed insulitis exhibited enhanced proinflammatory cy-
tokine production and proliferation when cultured with gliadin,
FIGURE 7. T cells isolated from the PLNs of
mice that develop insulitis respond to gliadin
stimulation. A, CD4+ T cells were isolated from
the PLNs of control and anti-CD25 mAb-treated
plus gliadin-sensitized mice and labeled with
CFSE. CD4+ T cells were incubated with APCs
with PT gliadin (right panels), BSA (center
panels), or media alone (left panels) for 4 d.
Proliferation was assessed with FACS analysis.
Cells were gated on live CD4+ lymphocytes.
Gated population represents the percentage of
proliferated cells. B, Quantification of pro-
liferation in A for control mice (n = 5) and anti-
CD25+ gliadin mice (n = 5). Data are represented
as mean 6 SEM; p values were computed using
an ANOVA for multiple comparisons. **p ,
0.01 versus other groups. TNF-a (C), IL-6 (D),
and MCP-1 (E) production was assessed in cell
culture supernatants from mice that developed
insulitis, using a cytometric bead array inflam-
mation kit. The dotted line represents the limit
of detection; p values were computed using an
unpaired t test.
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compared with culture with BSA or media alone. CD4+ T cells
isolated from the PLNs of control mice did not respond to gliadin
or BSA. These data suggest that a combination of mucosal dam-
age and breakdown in tolerance to gliadin led to insulitis in NOD-
DQ8 mice.
There is mounting evidence that a defect in the intestinal barrier
can promote T1D (61, 62). Several animal models of T1D have
demonstrated that increased intestinal permeability can be detec-
ted prior to the clinical onset of diabetes (63–65). Barrier dys-
function has also been observed in patients with T1D and in their
relatives (66, 67). A recent study in NOD mice has shown that
infection with Citrobacter rodentium resulted in increased in-
testinal permeability and accelerated onset of insulitis and di-
abetes (68). The results suggest an adjuvant role of intestinal
barrier dysfunction in diabetes development. In our study, 14-wk-
old NOD mice used as positive controls for insulitis exhibited
barrier dysfunction and severe insulitis. Because gliadin is known
to affect intestinal permeability in animal models of gluten sen-
sitivity and in humans with CD (41, 65, 69–71), we investigated
whether NOD-DQ8 mice developed gliadin-induced barrier dys-
function and insulitis. It has been suggested that the patients with
CD and the greatest risk of developing extraintestinal autoim-
munity are those who have had a longer duration of gluten ex-
posure (72). Studies in animal models and humans have shown
a reduction in T1D risk following implementation of a gluten-free
diet (29, 73, 74). We found that gliadin sensitization led to in-
creased tissue conductance and an enteropathy, characterized by
decreased villus-to-crypt ratios and increased IELs, that is remi-
niscent of moderate gluten sensitive enteropathy (75). In addition,
a proportion of gliadin-sensitized mice developed both anti-
gliadin IgG and anti-tTG IgA Abs. Similarly, a recent article us-
ing DQ8 transgenic mice that overexpress IL-15 in the lamina
propria found that mice fed gliadin developed anti-gliadin and
anti-tTG Abs, intraepithelial lymphocytosis, and IFN-g–producing
T cells, but lacked overt villous atrophy (76). Innate immune
responses toward gliadin can directly cause mucosal damage,
a process that involves production of IL-15. tTg also plays a key
role in modifying the anti-gliadin immune response in CD.
Whether these key innate immune responses have critical roles in
the development of mucosal damage in NOD-DQ8 still needs to
be elucidated. Despite these mucosal abnormalities in gliadin-
sensitized NOD-DQ8 mice, insulitis did not develop. These find-
ings suggest that loss of barrier function and moderate enteropathy
induced by gliadin are not sufficient, on their own, to induce
insulitis.
Recent studies have shown that inducible Tregs have a crucial
role in maintaining oral tolerance (77). In the MLNs, IL-2 and
TGF-b are required to induce production of CD4+CD25+Foxp3+
inducible Tregs from naive CD4+CD252 T cells (78). Migration to
the gut and expansion of these cells in the lamina propria by in-
testinal dendritic cells is crucial for the generation of oral toler-
ance (77, 78). In accordance with previous results using this
technique, we showed that treatment with anti-CD25 mAbs led to
partial depletion of Foxp3+ Tregs (47, 49, 52). Importantly, this
includes the inducible Treg population, which is critical for con-
trolling the immune response in the intestinal mucosa against oral
Ags (52, 77). The partial depletion was likely sufficient to disrupt
the immunologic balance between proinflammatory and regula-
tory mediators in NOD-DQ8 mice because insulitis developed
after sensitization with the relevant Ag in this model—gliadin.
However, anti-CD25 mAb-treated plus gliadin-sensitized mice did
not develop hyperglycemia or impaired glucose tolerance and
were not, therefore, clinically diabetic at the time they were an-
alyzed. Similarly, a study using anti-CD25 mAbs demonstrated
severe autoimmune gastritis only after administration of autoim-
mune gastritis target Ag plus anti-CD25 mAb treatment (53).
Although insulitis was evident in anti-CD25 mAb plus gliadin-
sensitized mice, a longer follow-up time after gliadin sensitization
may be needed for development of hyperglycemia and progression
to diabetes. However, the degree of insulitis in anti-CD25 plus
gliadin-sensitized mice was similar to the insulitis seen in 14-wk-
old NOD mice in our study and reported elsewhere (79). Impor-
tantly, several studies suggest that a proinflammatory environment
within the pancreatic islets can promote the development of di-
abetes. NOD-DQ8 mice have been shown to develop diabetes if
TNF-a is overexpressed in b islets (34). Other studies have shown
that the expression of the costimulatory molecule, B7-1, or IFN-a
within the islets can promote diabetes development, even in a di-
abetes-resistant background (80, 81). Our results indicate that
partial CD25+Foxp3+ T cell depletion prior to gliadin sensitization
was associated with islet infiltration in NOD-DQ8 mice. Extra-
intestinal inflammation in gliadin-sensitized NOD-DQ8 mice with
prior CD25+Foxp3+ cell depletion was localized to the pancreas,
as liver and lung tissues were normal.
CD4+ T cells isolated from the PLNs of mice that developed
insulitis responded to gliadin, and not to BSA. In NOD mice and
patients with T1D, diabetogenic T cells within the islets display
the gut homing marker a4b7 (82). Furthermore, the ligand for the
a4b7 integrin, MadCam-1, is expressed on the endothelium in the
pancreas and is upregulated during insulitis (83). It has been
shown that T cells isolated from the MLNs of 3-wk-old NOD mice
are able to induce the development of diabetes in NOD.SCID mice
more efficiently than lymphocytes isolated from peripheral lymph
nodes, pancreatic lymph nodes, and the spleen (84). This finding
suggests the initial priming of diabetogenic T cells may take place
in the gut and that activated T cells can home to the pancreas to
cause insulitis (84). In our model, oral sensitization to gliadin in
mice with partially depleted Tregs led to the production of gliadin-
responding T cells in the PLN. This gliadin-associated insulitis
could be permissive of T1D development in a genetically pre-
disposed host. Gliadin predominantly activates innate mechanisms
in animal models, but the adaptive immune system has also been
shown to be activated in transgenic HLA DQ8 mice (41, 45). We
demonstrate the presence of gliadin-responsive T cells in the
PLNs of NOD-DQ8 mice, providing an experimental setting
where both innate and adaptive immune mechanisms can be
studied within and outside the gut.
The current prevalence of T1D is estimated to double by 2020 in
children younger than 5 y, and ∼10% of children with T1D have
documented CD (10, 85). CD is common worldwide, with a dra-
matic increase in prevalence from just 0.2–0.9% during the last
five decades (6). With 95% of CD cases estimated to be currently
undiagnosed in North America, and the increasing incidence of
both diseases, the potential effects of gliadin intolerance on T1D
are alarming. Diabetes imposes a substantial cost burden on so-
ciety, in part because of its complications and comorbidities
(86, 87). Our results provide a model to elucidate the mechanisms
through which a common dietary intolerance may increase T1D
risk and test innovative dietary approaches to prevent and improve
metabolic control in T1D (88).
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